Loading...
XNASASND
Market cap8.15bUSD
Dec 20, Last price  
136.38USD
1D
-0.99%
1Q
-9.84%
Jan 2017
573.81%
IPO
581.90%
Name

Ascendis Pharma A/S

Chart & Performance

D1W1MN
XNAS:ASND chart
P/E
—
P/S
29.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.50%
Rev. gr., 5y
90.68%
Revenues
267m
+421.20%
15,583,00020,408,00013,983,0008,118,0004,606,0001,530,00010,581,00013,375,0006,953,0007,778,00051,174,000266,718,000
Net income
-481m
L-17.45%
1,250,0004,079,000-9,658,000-32,922,000-68,505,000-123,897,000-130,097,000-218,016,000-418,955,000-383,577,000-583,194,000-481,447,000
CFO
-467m
L-5.72%
-652,0006,310,000-18,403,000-43,466,000-60,179,000-95,099,000-138,802,000-175,936,000-271,548,000-417,649,000-495,699,000-467,361,000
Earnings
Feb 05, 2025

Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
URL
https://ascendispharma.dk/
IPO date
Jan 28, 2015
Employees
797
Domiciled in
DK
Incorporated in
DK

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
266,718
421.20%
51,174
557.93%
7,778
11.87%
Cost of revenue
457,849
391,761
299,390
Unusual Expense (Income)
NOPBT
(191,131)
(340,587)
(291,612)
NOPBT Margin
Operating Taxes
7,303
5,377
(367)
Tax Rate
NOPAT
(198,434)
(345,964)
(291,245)
Net income
(481,447)
-17.45%
(583,194)
52.04%
(383,577)
-8.44%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,263
(100,245)
346,279
BB yield
-0.12%
1.46%
-4.70%
Debt
Debt current
25,400
25,421
6,995
Long-term debt
717,658
592,147
202,927
Deferred revenue
14,213
2,964
Other long-term liabilities
155,075
157,950
2,964
Net debt
337,933
(148,311)
(618,048)
Cash flow
Cash from operating activities
(467,361)
(495,699)
(417,649)
CAPEX
(2,442)
(14,489)
(24,234)
Cash from investing activities
286,474
61,732
(110,579)
Cash from financing activities
134,292
396,773
351,387
FCF
(271,444)
(360,715)
(339,643)
Balance
Cash
399,439
735,455
682,064
Long term investments
5,686
30,424
145,906
Excess cash
391,789
763,320
827,581
Stockholders' equity
(2,422,792)
(1,591,929)
(530,916)
Invested Capital
3,076,435
2,530,327
1,525,242
ROIC
ROCE
EV
Common stock shares outstanding
56,287
56,072
54,772
Price
125.95
3.13%
122.13
-9.22%
134.53
-19.34%
Market cap
7,089,355
3.52%
6,848,048
-7.06%
7,368,445
-12.72%
EV
7,427,288
6,699,737
6,750,397
EBITDA
(172,220)
(322,629)
(276,221)
EV/EBITDA
Interest
44,065
50,487
3,911
Interest/NOPBT